MedTrace Logo

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

NCT03992417 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 955

Last updated 2025-07-11

No results posted yet for this study

Summary

Primary Objective:

To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD

Secondary Objectives:

* To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching)
* To assess the long-term effectiveness of Dupixent® in AD patients in a real-world setting
* To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in patients who receive Dupixent® for AD
* To collect safety data on study participants

Conditions

  • Dermatitis Atopic

Interventions

DRUG

Dupilumab SAR231893 (REGN668)

Pharmaceutical form: solution for injection Route of administration: subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-11
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Colombia
  • Czechia
  • Finland
  • France
  • Greece
  • Israel
  • Italy
  • Japan
  • Kuwait
  • Mexico
  • Netherlands
  • Norway
  • Portugal
  • Russia
  • Saudi Arabia
  • Spain
  • Taiwan
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03992417 on ClinicalTrials.gov